Literature DB >> 8283036

Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs.

M Shirai1, C D Pendleton, J Ahlers, T Takeshita, M Newman, J A Berzofsky.   

Abstract

CTL are a critical component of protective immunity against viral infections, but requirements for in vivo priming of CTL are not completely understood. Covalent linkage of a helper determinant to a CTL determinant, analogous to that required for cognate help for antibody production, does not appear to be necessary in vitro, but its necessity has not been extensively explored in vivo, especially at a molecular level. We previously defined peptides encompassing multideterminant regions of HIV-1 gp160 (cluster peptides) recognized by Th from mice and humans of multiple MHC types. To investigate the requirement for Th in the development of CTL in vivo, in the context of developing a synthetic peptide vaccine for HIV active in multiple strains of mice, we immunized with compound peptides representing an immunodominant CTL epitope, P18, of gp160, co-linearly synthesized at the C-terminus of three cluster peptides. Spleen cells from compound-peptide-immunized mice of three MHC haplotypes sharing the Dd class I MHC molecule but with different class II molecules exhibited enhanced gp160-specific CD8+ CTL activity and CD4+ Th. In contrast, immunization with P18 alone or a mixture of cluster peptide and P18 elicited only marginal CTL activity. These results imply a requirement for determinant linkage in CTL induction in vivo similar to that already well recognized for cognate help for antibody induction. The results also define promising peptide HIV vaccine candidates for induction of CTL, as well as neutralizing antibodies, in diverse MHC types.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8283036

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  44 in total

1.  Localization of CD4+ T cell epitope hotspots to exposed strands of HIV envelope glycoprotein suggests structural influences on antigen processing.

Authors:  S Surman; T D Lockey; K S Slobod; B Jones; J M Riberdy; S W White; P C Doherty; J L Hurwitz
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-03       Impact factor: 11.205

2.  Identification of the epitopes on HCV core protein recognized by HLA-A2 restricted cytotoxic T lymphocytes.

Authors:  H C Zhou; D Z Xu; X P Wang; J X Zhang; Y Huang; Y P Yan; Y Zhu; B Q Jin
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

3.  High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection.

Authors:  J D Ahlers; I M Belyakov; E K Thomas; J A Berzofsky
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

4.  Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design.

Authors:  Gang Zeng; Yong Li; Mona El-Gamil; John Sidney; Alexandro Sette; Rong-fu Wang; Steven A Rosenberg; Paul F Robbins
Journal:  Cancer Res       Date:  2002-07-01       Impact factor: 12.701

5.  A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L.

Authors:  Jeffrey D Ahlers; Igor M Belyakov; Masaki Terabe; Rima Koka; Debra D Donaldson; Elaine K Thomas; Jay A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-13       Impact factor: 11.205

Review 6.  The next wave of recombinant and synthetic anticancer vaccines.

Authors:  K R Irvine; N P Restifo
Journal:  Semin Cancer Biol       Date:  1995-12       Impact factor: 15.707

7.  Th-1 polarization is regulated by dendritic-cell comparison of MHC class I and class II antigens.

Authors:  William K Decker; Dongxia Xing; Sufang Li; Simon N Robinson; Hong Yang; David Steiner; Krishna V Komanduri; Elizabeth J Shpall
Journal:  Blood       Date:  2009-01-26       Impact factor: 22.113

Review 8.  Translating tumor antigens into cancer vaccines.

Authors:  Luigi Buonaguro; Annacarmen Petrizzo; Maria Lina Tornesello; Franco M Buonaguro
Journal:  Clin Vaccine Immunol       Date:  2010-11-03

9.  A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602).

Authors:  Craig L Slingluff; Sandra Lee; Fengmin Zhao; Kimberly A Chianese-Bullock; Walter C Olson; Lisa H Butterfield; Theresa L Whiteside; Philip D Leming; John M Kirkwood
Journal:  Clin Cancer Res       Date:  2013-05-07       Impact factor: 12.531

10.  Intranasal immunization with cytotoxic T-lymphocyte epitope peptide and mucosal adjuvant cholera toxin: selective augmentation of peptide-presenting dendritic cells in nasal mucosa-associated lymphoid tissue.

Authors:  A Porgador; H F Staats; Y Itoh; B L Kelsall
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.